EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE
https://doi.org/10.15829/1728-8800-2013-4-75-78
Abstract
Expert Consensus. Role of combination lipid-lowering therapy (simvastatin/ezetimibe 20/10 mg) in the correction of lipid metabolism disturbances in patients with chronic kidney disease.
About the Authors
A. Catapano
Президент Европейского общества атеросклероза
Italy
Italy
E. V. Shlyakhto
Президент РКО
Russian Federation
Russian Federation
A. I. Martynov
Президент РНМОТ
Russian Federation
Russian Federation
R. G. Oganov
акад. РАМН В.С. Моисеев
Russian Federation
Russian Federation
V. V. Kukharchuk
Russian Federation
M. V. Shestakova
Russian Federation
A. S. Ametov
Russian Federation
S. A. Boicov
Russian Federation
M. G. Bubnova
Russian Federation
S. V. Villevalde
Russian Federation
A. S. Galyavich
Russian Federation
Yu. A. Karpov
Russian Federation
J. D. Kobalava
Russian Federation
O. N. Koziolova
Russian Federation
References
1. National Guidelines. Chronic kidney disease: substantive provisions, the definition, diagnosis, screening, approaches to prevention and treatment (project). http://journal.nephrolog.ru/ckd/. Russian (Национальные рекомендации. Хроническая болезнь почек: основные положения, определение, диагностика, скрининг, подходы к профилактике и лечению (проект) http://journal.nephrolog.ru/ckd/).
2. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137–47.
3. Shestakova MV, Dedov II. Diabetes and chronic kidney disease. M. OOO “Medizinskoe informazionnoe agentstvo” 2009; 482 p. Russian (Шестакова М.В., Дедов И. И. Сахарный диабет и хроническая болезнь почек. М.: ООО «Медицинское информационное агентство» 2009; 482 с).
4. Keane WF, Tomassini JE, Neff DR, et al. Lipid-abnormalities in Patients with Chronic Kidney Disease. Contrib Nephrol 2011; 171:135–42.
5. Renal function and prediction of cardiovascular risk. National Guidelines. Cardiovascular Therapy and Prevention 2008; 7 (6), Suppl. 3. Russian (Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Национальные рекомендации. Кардиоваскулярная терапия и профилактика 2008; 7 (6), Приложение 3).
6. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 2012; 60 (5): 850–86.
7. ESC/EAS Guidelines for the management of dyslipidemias. Atherosclerosis 217S (2011); S1–44.
8. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplement 2013; 3 (1):1.
9. Diagnosis and correction of disorders of lipid metabolism in the prevention and treatment of atherosclerosis. National Guidelines. V review. Cardiovascular Therapy and Prevention 2012; 11 (4), Suppl. 1. Russian (Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Национальные рекомендации, V пересмотр. Кардиоваскулярная терапия и профилактика 2012; 11 (4), Приложение 1).
10. Venero CV, Thompson PD. Managing statin myopathy. Endocrinol Metab Clin North Am 2009; 38: 121–36.
11. Baigent C, Landray MJ, Reith C, et al. SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 2011; 377 (9784): 2181–92. Epub 2011 Jun 12.
12. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78.
13. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomized trials. Lancet 2010; 376: 1670–81.
14. Shestakova MV. Diabetes and chronic kidney disease: modern diagnostic and treatment. Vestnik RAMN 2012; 1: 45–50. Russian (Шестакова М.В. Сахарный диабет и хроническая болезнь почек: современная диагностика и лечение. Вестник РАМН 2012; 1: 45–50).
15. Leiter LA, Betteridge DJ, Farnier M, et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diab Obes Metab 2011; 13: 615–28.
16. Ravid Z, Bendayan M, Delvin E, et al. Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors. Am J Physiol Gastrointest Liver Physiol 2008; 295: G873-85.
17. Instruction for use of the drug Inegy. Russian (Инструкция по медицинскому применению лекарственного препарата Инеджи).
Review
For citations:
Catapano A., Shlyakhto E.V., Martynov A.I., Oganov R.G., Kukharchuk V.V., Shestakova M.V., Ametov A.S., Boicov S.A., Bubnova M.G., Villevalde S.V., Galyavich A.S., Karpov Yu.A., Kobalava J.D., Koziolova O.N. EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Cardiovascular Therapy and Prevention. 2013;12(4):75-78. (In Russ.) https://doi.org/10.15829/1728-8800-2013-4-75-78
Views:
724
Email this article 
